BC Cancer ST Program Updates for August 2025

| AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build

What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
  - Click **Yes** to accept the new version
  - **Do not** use the Copy Forward functionality to ensure that the updates apply

- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning)

Please see this month's changes below.

Protocols: UMYTEC
Cycles/PowerPlans: ONCP MY UMYTEC teclistamab Cycles 2+
Changes: Labs Phase: ● **Added order** under "If clinically indicated": **Hepatitis B Viral Load** (Rx monitoring): *Blood, once, Order for future visit.*
Versioning: Yes
Jira: CST-324401

Protocol: SMAJNIV, SMAJNIV, SMAJNIV4, SMAJNIV4, SMAJPEM,SMAJPEM, SMAJPEM6, SMAJPEM6
Cycles/PowerPlans: All associated treatment PowerPlans and Regimens
Changes: In Regimens**:** • Updated protocol title in Description per protocol   ○ Example: ONC SM SMAJNIV

ONC SM SMAJNIV (Pending)

▼ Hide additional details

Regimen description: Adjuvant Treatment of Resected Melanoma using Nivolumab

In Chemotherapy Phase:

- Updated **Clinical Decision Support** Note: *Link to Protocol: Adjuvant Treatment of Resected Melanoma using Nivolumab.*

  ○ Example from ONCP SM SMAJNIV:

ONCP SM SMAJNIV - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 18-Jul-2025 08:00 P

		Component	Day 1 Future Pending *Est. 18-Jul-2025 08:0... Actions ▽
		Link to Protocol: Adjuvant Treatment of Resected Melanoma using Nivolumab	

- Updated **Clinical Decision Support Note**: *Order Weekly Nursing Assessment (Optional).*

Procedural/Schedulable Orders
Order Weekly Nursing Assessment (Optional)

Versioning: Yes

Jira: CST-322994

Protocol: LULACATRT

Cycles/PowerPlans: All Associated PowerPlans

Changes:

- **Inactivated** ONCP LU LULACATRT Consolidation PowerPlan.

- **Updated** regimen to remove the Inactivated plan.

- **Renamed** PowerPlan from *ONCP LU LULACATRT Concurrent* to *ONCP LU LULACATRT.*

- **Updated** the Pre-Chemo Metrics: *[…] within 48 hours.*

Versioning: Yes
Jira: CST-323939

Protocols: LYCLLZANU and ULYWMZANU

Cycles/PowerPlans: Associated treatment Powerplans

Changes:

Updates to the Prescriptions phase of **ONCP LY LYCLLZANU (PO)** and **ONCP LY ULYWMZANU (PO)**:

- Removed the 80mg BID options from the Zanubrutinib order.

		Component	Status	Dose ...	Details

ONCP LY LYCLLZANU (PO), Prescriptions (Future Pending)

| Link to Protocol: Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Zanubrutinib |
| Revised: 1 May 2025 |
| Pre-Chemo Metrics |
| Within 7 days prior to Cycle 1, then within 14 days prior to start of subsequent cycles: |
| Neutrophils Greater Than or Equal to 1.5 x10^9/L |
| Platelet Count Greater Than or Equal to 75 x10^9/L |
| Treatment Regimen |

☑ zanubrutinib — 160 mg, PO, BID, drug form: tab, dispense qty: 30 day

Dose modification:

☐ zanubrutinib — Select an order sentence
- 160 mg, PO, qdaily, drug form: tab, dispense qty: 30 day
- 160 mg, PO, qdaily, drug form: tab, dispense qty: 60 day
- 160 mg, PO, qdaily, drug form: tab, dispense qty: 90 day
- 80 mg, PO, qdaily, drug form: cap, dispense qty: 30 day
- 80 mg, PO, qdaily, drug form: cap, dispense qty: 60 day
- 80 mg, PO, qdaily, drug form: cap, dispense qty: 90 day

Versioning: Yes

Jira: CST-328891

Net New Protocols: LUAVPGCEM, LUAVPPCEM, LUAVPCCEM, LUAVCEMF, UGUPAJENZ, USMLACEM

Net New Protocols:
- ONC LU LUAVPGCEM CARBOplatin Option
- ONC LU LUAVPGCEM CISplatin Option
- ONCP LU LUAVPGCEM Pretreatment Plan
- ONCP LU LUAVPGCEM CARBOplatin Option Cycles 1 to 6
- ONCP LU LUAVPGCEM CISplatin Option Cycles 1 to 6
- ONCP LU LUAVPGCEM Cycles 7+

- ONC LU LUAVPPCEM CARBOplatin Option
- ONC LU LUAVPPCEM CISplatin Option
- ONCP LU LUAVPPCEM Pretreatment Plan
- ONCP LU LUAVPPCEM CARBOplatin Option Cycles 1 to 6
- ONCP LU LUAVPPCEM CISplatin Option Cycles 1 to 6
- ONCP LU LUAVPPCEM Cycles 7+

- ONC LU LUAVPCCEM
- ONCP LU LUAVPCCEM Pretreatment Plan
- ONCP LU LUAVPCCEM Cycles 1 to 6
- ONCP LU LUAVPCCEM Cycles 7+

- ONC LU LUAVCEMF
- ONCP LU LUAVCEMF Pretreatment Plan
- ONCP LU LUAVCEMF

- ONC GU UGUPAJENZ
- ONCP GU UGUPAJENZ Pretreatment Plan
- ONCP GU UGUPAJENZ (PO)

- ONC SM USMLACEM
- ONCP SM USMLACEM Pretreatment Plan
- ONCP SM USMLACEM

Jira: CST-324597, CST-324147, CST-324139, CST-323016, CST-323298, CST-323014

Jira Ticket #	CST-324597, CST-324401, CST-324147, CST-324139, CST-323939, CST-323298, CST-323016, CST-323014, CST-322994, CST-328891
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	**CST Phone Support: 1-844-214-7444**